Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > IR responce

<< Previous

Bullboard Posts

Next >>

Comment by crow27on Feb 11, 2021 1:40pm

93 Views

Post# 32542381

RE:RE:RE:RE:RE:IR responce

The real question is how long will it take Nuance to bring this to market? All I know is that when Covid hit China they built a hospital in 6 days.
They can move this very fast in my eyes and I think it is because of the huge gains on all fronts, not only the money.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China